Nucleai and Mayo Clinic BioPharma Diagnostics Announce Strategic Collaboration to Transform Digital Pathology for Drug Development and Clinical Practice
June 04 2023 - 8:00AM
Business Wire
Nucleai, a leading provider of artificial intelligence (AI)
solutions for pathology and spatial biology, and Mayo Clinic
BioPharma Diagnostics are pleased to announce a strategic
collaboration to bring world-class digital pathology solutions,
technologies, and services to support drug development and clinical
practice. This collaboration combines Nucleai’s AI-powered spatial
biology technology with Mayo’s longitudinally annotated,
multi-modal data sets, world-class lab services, and clinical
diagnostic footprint.
"We are excited to work closely with Mayo to bring spatial
biology to the hands of the biopharma industry, clinicians and
researchers,” said Avi Veidman, CEO of Nucleai. "By combining Mayo
Clinic's extensive multi-modal datasets, laboratories, and clinical
expertise with Nucleai's advanced AI platform, we can bring scale
and impact to the entire precision medicine landscape.”
Through this collaboration, Nucleai and Mayo Clinic will focus
on several distinct offerings to support drug development including
biomarker discovery and validation, end-to-end spatial biology
testing and algorithm deployment for clinical trials and diagnostic
use.
About Nucleai:
Nucleai is an AI-powered spatial biology company with a mission
to transform drug development and clinical treatment decisions by
unlocking the power of pathology data. Nucleai provides
pharmaceutical companies, contract research organizations, and
diagnostics laboratories with a state-of-the-art AI platform to
improve clinical trials and clinical decision-making. For more
information, please visit www.nucleai.ai.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230604005025/en/
Jonathan Daniels VP, Head of Business Development and Strategy
Email: jonathan@nucleai.ai